Alvogen acquires Korean Dream Pharma for US$ 187 million

Alvogen announced today that it has acquired Dream Pharma (“Dream”) in South Korea for US$ 187 million in cash. Dream will be acquired through Alvogen’s Asian subsidiaries and, on completion, will create one of the largest generic pharmaceutical companies in South Korea. 

Read full story

Robert Wessman, CEO of Alvogen with senior management at Kunwha during his visit in August

Robert Wessman, CEO of Alvogen with senior management at Kunwha during his visit in August


Alvogen is a multinational pharmaceuticals company

Alvogen is an international privately-owned specialty pharmaceutical company focused on the development, manufacturing and marketing of generic pharmaceuticals, biosimilar products and OTC‘s The company is committed to building the next-generation generics company through the strategic selection of products, partners and markets, and the utilization of an effective consolidated global supply chain. 

A unique portfolio of high quality and high barrier products fuels our targeted growth strategy. Currently, Alvogen has commercial operations in 30 countries around the world. Robert Wessman is the Chairman and CEO of Alvogen and leads its global expansion. 

View company profile

Fast Growing Product Portfolio

We focus on difficult-to-make and high-value formulations and pursue first-to-file opportunities in the U.S. market. With more than 200 pharmaceutical projects in global development and registration, Alvogen markets and distributes products in over 30 countries. Product formulations manufactured and sold by Alvogen include solid oral dosage, soft gelatin capsules, modified release tablets, transdermals, creams, ointments and injectables.  

Our product pipeline is filled by selections from internal R&D candidates, in-licensed products, fostering strategic partnerships and targeted portfolio acquisitions and consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. 

Product portfolio

Building Young Lives

Our global charity fund, Better Planet, has allowed us to touch the lives of thousands of children through educational programs and immediate relief support. On a global level we work with UNICEF and the Red Cross but in local markets with various charity organizations.

We like to make the world a better place for children and Better Planet is designed to take on tough challenges in the global community and involves the Alvogen family in 30 countries. We reach out to our local communities to make a difference through Alvogen Citizenship and other local initiatives.

Learn more

Alvogen is open for collaborations

Collaboration with other companies in our industry, academia, government and non-governmental organizations is fundamental to our strategic priorities of growing a diversified, global business and delivering a wide range of valuable products.

At Alvogen, we value partnerships and collaboration. Our future strategy relies heavily on our strategic selection of people and successful partnerships around the world. We believe, that by working together, we can discover, develop, and deliver the best value for our customers.

Become a partner
Join us

Say hello to Fun!

Alvogen is not a conventional company, and we don’t intend to become one. We are not afraid to follow an unbeaten path in our efforts to differentiate, provide innovative solutions to our customers and drive our business forward. We have defined an ambitious strategic roadmap to guide us towards our goal to become a top ten global player by 2016 and we will have fun doing it.

Alvogen has offices around the world, from Bangalore to Bulgaria, but regardless of where we are, we nurture our values and a positive working environment by hiring street-smart, innovative, local people who share our competitive spirit and passion to stand out and succeed.

Join our team!